Grinstein S, Furuya W
Biochim Biophys Acta. 1982 Mar 23;686(1):55-64. doi: 10.1016/0005-2736(82)90151-1.
Calmodulin copurifies with platelet plasma membranes isolated by glycerol-induced lysis and density gradient centrifugation. These membranes also bind 125I-labeled calmodulin in vitro in the presence of Ca2+. Binding is largely reduced by replacing Ca2+ by Mg2+ or by addition of an excess unlabeled calmodulin. The specific component of binding is saturable, with an apparent Kd of 27 nM and a maximum of 15.9 pmol binding sites per mg of membrane protein. This is equivalent to approx. 4100 binding sites per platelet. Binding was inhibited by addition of phenothiazines, a group of calmodulin antagonists. Half-maximal inhibition was attained with approx. 20 microM trifluoperazine or 50 microM chlorpromazine. In contrast, chlorpromazine-sulfoxide which is inactive towards calmodulin, did not affect the binding. Calmodulin binding polypeptides of the plasma membrane were identified by a gel-overlay technique. A major calmodulin-binding component of molecular weight 149000 was detected. Binding to this band was Ca2+-dependent and inhibited by chlorpromazine. The molecular weight of this polypeptide is similar to that of glycoprotein I and also that of the red cell (Ca2+ + Mg2+)-stimulated ATPase, which is known to bind calmodulin. The possible role of calmodulin in platelet activation is analysed.
钙调蛋白与通过甘油诱导裂解和密度梯度离心分离的血小板质膜共纯化。在体外,这些膜在Ca2+存在的情况下也能结合125I标记的钙调蛋白。用Mg2+替代Ca2+或加入过量未标记的钙调蛋白可大大降低结合。结合的特异性成分是可饱和的,表观解离常数(Kd)为27 nM,每毫克膜蛋白的最大结合位点为15.9 pmol。这相当于每个血小板约4100个结合位点。加入吩噻嗪类药物(一类钙调蛋白拮抗剂)可抑制结合。约20 μM三氟拉嗪或50 μM氯丙嗪可达到半数最大抑制。相比之下,对钙调蛋白无活性的氯丙嗪亚砜不影响结合。通过凝胶覆盖技术鉴定了质膜的钙调蛋白结合多肽。检测到一种分子量为149000的主要钙调蛋白结合成分。与该条带的结合依赖于Ca2+,并受到氯丙嗪的抑制。该多肽的分子量与糖蛋白I以及红细胞(Ca2+ + Mg2+)刺激的ATP酶的分子量相似,已知后者能结合钙调蛋白。分析了钙调蛋白在血小板活化中的可能作用。